RxDoctor Payments Data

Elizabeth Vaught, NP

Adult Health · Dyer, INNPI 1093175630

Payments from drug & device makers

$1,497in general payments, 2019–2025

Across 16 payments — averaging $93.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$886
  • AstraZeneca$114
  • Boehringer Ingelheim$114
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$100
  • Surmodics, Inc.$99
  • Abiomed$73
  • plus $110 from 4 others

What the payments were for

  • Travel & lodging$24516%
  • Food & beverage$1,25284%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,497 in reported general payments places this provider in the 70th percentile of 391 adult health providers in Indiana.

See all adult health providers in Indiana

Medicare billing

Part B allowed, 2024
$149,766
Medicare patients
715
Services billed
3,222

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban348$397,727
XareltoRivaroxaban138$189,615
EntrestoSacubitril/Valsartan143$183,162
Dofetilide94$40,058
Metoprolol Succinate544$8,912
Flecainide Acetate126$8,187
FarxigaDapagliflozin Propanediol13$7,444
Diltiazem 24hr Er (Cd)Diltiazem Hcl59$2,460
Atorvastatin Calcium161$1,599
Metoprolol Tartrate207$1,523
Pantoprazole Sodium121$1,458
Amiodarone Hcl84$1,334
ClopidogrelClopidogrel Bisulfate78$1,125
Lisinopril120$1,065
SotalolSotalol Hcl55$1,011

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$19$183,162143 claims
AstraZenecaFarxiga$114$7,44413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 391 adult health providers in Indiana.

Other adult health in Dyer

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →